SMYD2

Across TCGA pan-cancer cohorts, SMYD2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SMYD2 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher SMYD2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SMYD2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and CCRCC show a favorable association.

UCEC, PDAC, and LUAD are the cancer types where SMYD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	III,IV	1.000	0.449	.010	28	view →
PDAC	DFS	Median	All	0.678	0.835	.020	10	view →
LUAD	DFS	Tertile	All	0.549	0.772	.026	6	view →
LSCC	DFS	Median	All	0.733	0.844	.033	3	view →
CCRCC	DFS	Tertile	II,III,IV	0.859	0.286	.035	2	view →
HNSC	DFS	Median	II,III,IV	0.704	0.839	.033	1	view →
GBM	DFS	Tertile	All	0.844	0.584	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SMYD2–UCEC (OS)

Open the UCEC breakdown →